SetPoint Medical Appoints Tyler Binney to Its Board of Directors
'Tyler has a strong track record of building successful commercial organizations and delivering sustained growth in new markets,' said Murthy V. Simhambhatla, Ph.D., Chief Executive Officer of SetPoint Medical. 'His experience bringing novel, category-creating technologies to market will be an incredible asset to our team as we work to provide patients with access to our innovative neuroimmune modulation platform.'
With over 20 years of proven leadership experience in the medical device industry, Mr. Binney most recently served as President and Chief Executive Officer of Relievant Medical Systems, which Boston Scientific acquired in November 2023 for an upfront payment of $850 million, plus performance-based earnouts. Previously, he served as President and General Manager of the Interventional Urology Business Unit at Teleflex, and as Vice President of Sales at NeoTract, where he led the successful commercialization of the UroLift® System, contributing to its $1.1 billion acquisition by Teleflex.
'What SetPoint is doing in the field of neuroimmune modulation is truly groundbreaking,' said Tyler Binney. 'This team is on the verge of transforming the treatment of chronic autoimmune conditions, and I look forward to contributing my experience as they accelerate their strategy to commercialize this platform technology.'
About SetPoint Medical
SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating people living with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate neuroimmune pathways to produce a systemic anti-inflammatory and immune-restorative effect. SetPoint Medical's platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. For more information, visit www.setpointmedical.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Looking for a Growth Stock? 3 Reasons Why Fabrinet (FN) is a Solid Choice
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task. In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. Our proprietary system currently recommends Fabrinet (FN) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better. While there are numerous reasons why the stock of this company that assembles optical, electro-mechanical and electronic devices for other companies is a great growth pick right now, we have highlighted three of the most important factors below: Earnings Growth Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for Fabrinet is 25.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 17.5% this year, crushing the industry average, which calls for EPS growth of 15.9%. Cash Flow Growth Cash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds. Right now, year-over-year cash flow growth for Fabrinet is 14.4%, which is higher than many of its peers. In fact, the rate compares to the industry average of -14%. While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 17.1% over the past 3-5 years versus the industry average of 5.1%. Promising Earnings Estimate Revisions Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. The current-year earnings estimates for Fabrinet have been revising upward. The Zacks Consensus Estimate for the current year has surged 3.6% over the past month. Bottom Line While the overall earnings estimate revisions have made Fabrinet a Zacks Rank #2 stock, it has earned itself a Growth Score of B based on a number of factors, including the ones discussed above. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This combination positions Fabrinet well for outperformance, so growth investors may want to bet on it. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fabrinet (FN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Tandem, Insulet monitoring CMS payment proposal for diabetes tech
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medtech executives discussed planned changes to how the Centers for Medicare and Medicaid Services could pay for diabetes technology in earnings calls this week. Insulin pump makers Insulet and Tandem Diabetes Care don't expect much of an impact on their business from the proposed changes, but said they would be monitoring the policy. In June, CMS issued a proposed rule that would seek to include insulin pumps and continuous glucose monitors in a competitive bidding program. The rule would also change payments to a monthly rental schedule instead of a contract where the devices are paid for upfront. RBC Capital Markets analyst Shagun Singh expects Tandem and Medtronic to be impacted the most, 'as the new proposal would allow for competitive switching,' she wrote in a July 1 research note. Singh expects Insulet to see less of an impact as the company already uses a 'pay-as-you-go' model, and Dexcom's and Abbott's CGMs are already sold on a monthly bundle basis. Tandem CFO Leigh Vosseller said on an earnings call Wednesday that the company does not expect the changes to have a material impact on the company's business, and 'we anticipate it could help drive more people to pump therapy.' Currently, traditional Medicare makes up less than 10% of Tandem's sales. Vosseller said the payment change would shift pump reimbursement from a 13-month rental to a pay-as-you-go model. Tandem, which currently sells most of its pumps through a durable medical equipment model, plans to begin selling supplies for its t:slim X2 pump through the pharmacy channel starting in the fourth quarter. 'Transitioning to a pay-as-you-go model is something that we've contemplated anyway from a commercial perspective as we've pursued the pharmacy channel,' Vosseller said. She added that Tandem will be participating in the comment period and anticipates final rulings in November. Tandem lowered its earnings forecast for U.S. sales in 2025 to $700 million for the year, down from a previous range of $725 million to $730 million. CEO John Sheridan said the change was due to a new market entrant that has built a larger-than-expected sales team, and initiatives that are still in progress to modernize Tandem's systems and grow its salesforce. The company also disclosed a recall related to a speaker problem with its devices, which has been associated with 59 injuries. Tandem's stock price was down roughly 20% to $11.52 at market close Thursday. Insulet, Dexcom expect little impact Insulet expects little impact from the CMS changes. CEO Ashley McEvoy told investors Thursday that the company's devices are already sold on a pay-as-you-go basis, as the company does almost all of its sales through the pharmacy channel. Insulet's patch pumps are covered under Medicare Part D, which covers prescription drugs, and McEvoy doesn't think they will be eligible for competitive bidding under Part B, which covers durable medical equipment. 'We are going to continue to engage with CMS to really talk about the benefits of our differentiated Omnipod 5 technology and how we improve care for people with diabetes,' McEvoy said. Insulet raised its sales expectations for 2025, now anticipating growth of 24% to 27%, from a previous range of 19% to 22% Dexcom Chief Operating Officer Jake Leach also addressed the CMS competitive bidding proposal, saying about 15% of the company's business is fee-for-service Medicare. Leach, who will become CEO of Dexcom in January, said on an earnings call in July that 'we feel very comfortable about the value that we bring for the price of our product.' He added that Dexcom also wants to ensure there's not an interruption to care for people on Medicare as has happened in previous versions of competitive bidding. CFO Jereme Sylvain said he expects the bidding process to start no earlier than 2027, based on historical precedent. Recommended Reading Tandem insulin pump malfunction linked to 59 injuries Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Masimo appoints several senior execs, resolves cyber incident
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 revenue: $370.9 million 7.9% increase year over year Net income from continuing operations: $44.9 million 81% increase year over year Masimo said it has implemented measures that reduced its tariff burden by more than half and resolved a cybersecurity incident that occurred in the spring. The patient monitoring company said second-quarter revenue met expectations, and adjusted earnings per share grew 46% year over year due to continuing cost structure actions under new CEO Katie Szyman. The executive joined Masimo in February from BD, taking the job months after founder Joe Kiani left the company following a protracted proxy battle. On a Tuesday earnings call, Szyman unveiled several senior leadership hires, including Greg Meehan in the role of chief commercial officer. Also named were Huimin Wang as president of Japan and Asia Pacific, Tim Benner as chief marketing and strategy officer, Linnette Torres as executive vice president of quality and regulatory, and Giri Chodavarapu as chief information officer. In addition, Omar Ahmed was promoted to chief technology and innovation officer. Still, analysts raised concerns about the lack of a contract renewal with longtime customer Philips, weighing on Masimo's shares. The status of Masimo's relationship with Philips was a topic on the call, with one analyst pointing to a competitor's renewed partnership with the equipment manufacturer. Medtronic announced last month that it signed a multiyear agreement with Philips in patient monitoring. Szyman said Masimo's agreement with Philips is still in place, and the companies are in talks to continue the partnership 'well into the future.' The relationship with Philips remains 'very strong,' she said. Masimo, which boosted its full-year earnings forecast, said the update includes a $17 million to $19 million increase to its cost of sales from tariffs and 25-cent impact on earnings per share, down from the range of 45 cents to 50 cents forecast in May. Including the impact of tariffs, adjusted earnings are now projected in a range of $5.20 to $5.45 per share, up from the previous $4.80 to $5.15. Cyberattack and Sound United sale CFO Micah Young said Masimo incurred net expenses of about $4.5 million to recover and fortify its systems with the help of a team of outside experts, following a spring cybersecurity incident. Masimo discovered unauthorized activity on its on-premises network on April 27. The attack on some of its manufacturing facilities disrupted the company's website and several computer systems. When it disclosed the incident in May, the company warned the attack had affected its ability to fulfill orders. The divestiture of Sound United, announced in May, remains on track to close by the end of the year, Young said. Masimo plans to sell the consumer audio business for $350 million to Samsung Electronics' Harman International unit, to focus on its professional healthcare business. Recommended Reading Masimo says cyberattack has impacted its ability to fulfill orders Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
